

Edmond Kwan MBBS PhD FRACP

Eastern Health Clinical School, Monash University
Biomedicine Discovery Institute, Monash University
Level 2, 5 Arnold Street, Box Hill, VIC 3128 Australia
Email: edmond.kwan@monash.edu

ACADEMIC & HOSPITAL APPOINTMENTS

2024 – Present	Lab Head and Senior Research Fellow Eastern Health Clinical School & Biomedicine Discovery Institute Monash University, Melbourne, Australia
2024 – Present	Consultant Medical Oncologist (Genitourinary Oncology Service) Eastern Health, Cancer Services, Melbourne, Australia
2021 – 2024	Postdoctoral Fellow (Supervisors Prof Kim Chi & A/Prof Alex Wyatt) BC Cancer –Vancouver Centre, Vancouver, British Columbia, Canada Department of Urologic Sciences, University of British Columbia
2020 – 2024	Honorary Adjunct Senior Lecturer Faculty of Medicine, Nursing and Health Sciences, Monash University
2017 – 2021	Consultant Medical Oncologist (Genitourinary Oncology Service) Principal Investigator, Urology-Oncology Clinical Trials Program Monash Health, Department of Medical Oncology, Melbourne, Australia

EDUCATION & TRAINING

2017 – Present	Fellow of the Royal Australasian College of Physicians (FRACP) Speciality: Physician - Medical Oncology AHPPRA Registration: MED0001612007
2017 – 2020	Doctor of Philosophy (PhD) School of Clinical Sciences, Monash University Faculty of Medicine, Nursing and Health Sciences, Monash University <i>Whole blood transcriptomic analysis as biomarkers in metastatic prostate cancer</i> Supervisors: A/Prof Arun Azad, Prof Eva Segelov
2016 – 2017	Phase I / Early Drug Development Fellow Peter MacCallum Cancer Centre, Melbourne, Australia Royal Melbourne Hospital, Melbourne, Australia
2014 – 2016	Advanced Trainee – Medical Oncology Monash Health, Melbourne, Australia Western Health, Melbourne, Australia
2010 – 2014	Internship and Basic Physician Trainee General Medicine Division, Royal Melbourne Hospital, Melbourne, Australia
2005 – 2009	Bachelor of Medicine, Bachelor of Surgery (MBBS) Bond University, Gold Coast, Australia <i>Dux of Core Clinical Rotations (2008)</i> <i>Dux of Elective / Speciality Clinical Rotations (2009)</i>

RESEARCH FUNDING

Eastern Health Institute Oliver Blumberg Prostate Cancer Research Grant (2026-2027) AUD \$100,000
Redefining genotyping in metastatic prostate cancer: a liquid biopsy strategy for equitable access
Responsibilities: Principal Investigator

Viertel Charitable Foundation Clinical Investigator Award (2026) AUD \$90,000
Toward a clinically informative epigenomic liquid biopsy in metastatic prostate cancer
Responsibilities: Principal Investigator

ANZUP Below the Belt Research Fund (2025-2026) AUD \$50,000
Serial profiling of oncogenic biomarkers through treatment in liquid biopsy for investigating heterogeneity and treatment response in metastatic prostate cancer
Responsibilities: Co-Principal Investigator

MPCCC Cancer Research Resource Grant (2025) AUD \$85,000
Monash Cancer Donor Program
Responsibilities: Associate Investigator

ANZUP Synchrony Fellowship (2024-2025) AUD \$250,000
Multimodal ctDNA analysis and novel imaging to inform precision use of PSMA radioligand therapy: an integrative biomarker analysis of the phase 2 TheraP trial
Responsibilities: Principal Investigator

Prostate Cancer Foundation Challenge Award (2023-2025) US \$1,000,000
ctDNA determinants of resistance to Lu-PSMA versus taxane-based chemotherapy
Responsibilities: Young Investigator

Prostate Cancer Foundation Young Investigator Award (2022-2024) US \$225,000
Integrated tissue and circulating tumour DNA profiling to risk stratify de novo metastatic hormone-sensitive prostate cancer prior to systemic therapy
Responsibilities: Principal Investigator

University of British Columbia Killam Postdoctoral Research Fellowship (2022-2023) CAD \$100,000
Plasma DNA profiling to identify genomic drivers of resistance to androgen-receptor therapies in metastatic hormone-sensitive prostate cancer
Responsibilities: Principal Investigator

Canadian Institutes of Health Research (2021-2024) CAD \$734,400
Genomic dissection of de novo metastatic prostate cancer prior to treatment
Responsibilities: Associate Investigator

Cancer Council Australia Postdoctoral Research Fellowship (2021) AUD \$80,000
Comprehensive circulating nucleic acid analysis to identify biomarkers for immune checkpoint inhibitors (ICI) in metastatic castration-resistant prostate cancer (mCRPC)
Responsibilities: Principal Investigator

Astellas Investigator Initiated Research Grant (2021-2023) AUD \$392,603

Comprehensive circulating nucleic acid analysis of metastatic castration-resistant prostate cancer: characterising predictive, prognostic and resistance biomarkers with a novel 'all-in-one' assay

Responsibilities: Associate Investigator

National Health & Medical Research Council Postgraduate Scholarship (2017-2020) AUD \$125,000

Whole blood transcriptomic analysis in advanced prostate cancer: predictive and prognostic utility of androgen receptor variants and other prostate-cancer related genes

Responsibilities: Principal Investigator

Movember Prostate Cancer Research Alliance Fund (2019) AUD \$5,400,000

PRECEPT: Prostate Cancer Prognosis and Treatment

Responsibilities: Associate Investigator

ANZUP Below the Belt Research Fund (2018) AUD \$50,000

Application of a multi-gene prostate circulating tumour DNA (ctDNA) panel in men with metastatic hormone-sensitive prostate cancer (mHSPC)

Responsibilities: Co-Principal Investigator

Ian Potter Foundation (2010) AUD \$30,000

Gold Coast Cardiovascular DNA Bank

Responsibilities: Associate Investigator

PUBLICATIONS

To view a full list of my published work, please visit **My Bibliography**:

PubMed: <https://www.ncbi.nlm.nih.gov/myncbi/1RQvgzm6zIL5y/bibliography/public/>

Google Scholar: <https://bit.ly/39Jzdmh>

First/corresponding author publications (ordered by recency):

1. Virtanen T*, **Kwan EM***, Parekh K, Bacon JVW, Huang CF, Yu IPL, Ryyppö L, Bernales C, Donnellan G, Tam C, Sipola J, Nikkola J, Vandekerhove G, Tolmeijer T, Kukkonen K, Adelia, Egl BJ, Finch D, Gagnon R, Takieldeen Y, Hardy E, Khalaf D, Kollmannsberger C, Lavoie J, Maurice-Dror C, Miller S, Nappi L, Noonan K, Parimi S, Riminchan A, Sartori-Mueller E, Soleimani M, Vergidis J, Zulfiqar M, Hansen A, Hotte S, Jafri M, Kolinsky M, Mukherjee SD, Ong M, Rose AAN, Tu W, Winquist E, Bergman AM, van der Zande K, Zwart W, Mehra N, van Erp NP, Zhao JL, Rathkopf D, Barbieri C, Quigley D, Nykter M, Lack NA, Chi KN, Annala M, Wyatt AW. Repertoire and clinical hierarchy of AR locus alterations in castration-resistant prostate cancer. *Ann Oncol* 2025. Accepted * Co-first author
2. **Kwan EM***, Ng SWS*, Tolmeijer SH, Emmett L, Sandhu S, Buteau JP, Iravani A, Joshua AM, Francis RJ, Subhash V, Lee S, Scott AM, Martin AJ, Stocker MR, Donnellan G, Annala M, Herberts C, Davis ID, Hofman MS, Azad AA, Wyatt AW. Lutetium-177-PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial. *Nat Med* 2025;31:2722-2736. PMID [40425844](#) * Co-first author
3. Sipola J*, Munzur AD*, **Kwan EM***, Seo CCY, Hauk BJ, Parekh K, Liao YJ, Bernales CQ, Donnellan G, Bloise I, Fung E, Ng SWS, Wang G, Vandekerhove G, Nykter M, Annala M, Maurice-Dror C, Chi KN, Herberts C, Wyatt AW, Takeda D. Plasma cell-free DNA chromatin immunoprecipitation is associated

with phenotypic and clinical heterogeneity in advanced prostate cancer. *Cancer Res* 2025;85:791-807. PMID [39652574](#) * Co-first author

4. **Kwan EM**, Spain L, Anton A, Gan CL, Garrett L, Chang D, Liow E, Bennett C, Zheng T, Yu J, Dai C, Du P, Jia S, Fettke H, Abou-Seif C, Kothari G, Shaw M, Parente P, Pezaro C, Tran B, Siva S, Azad AA. Avelumab combined with stereotactic ablative body radiotherapy (SABR) in metastatic castration-resistant prostate cancer (mCRPC): the phase 2 ICE-PAC clinical trial. *Eur Urol* 2022; 81:253-262. PMID [34493414](#)
5. **Kwan EM**, Wyatt AA, Chi KN. Towards clinical implementation of circulating tumor DNA in metastatic prostate cancer: opportunities for integration and pitfalls to interpretation. *Front Oncol* 2022;12:1054497. PMID [36439451](#)
6. **Kwan EM**, Wyatt AA. AR genomic alterations and treatment resistance in metastatic prostate cancer. *Prostate* 2022;82 Suppl 1:S25-S36. PMID [35657159](#)
7. Davies A, Azad AA, **Kwan EM**. Genomic alterations to guide treatment selection in metastatic prostate cancer. *Crit Rev Oncog* 2022;27(1):61-80. PMID [35993979](#)
8. **Kwan EM**, Dai C, Fettke H, Hauser C, Docanto MM, Bukczynska P, Ng N, Foroughi S, Graham LK, Mahon K, Tan W, Wang X, Zhao Z, Zheng T, Zhou K, Yu J, Du P, Horvath LG, Jia S, Kohli M, Azad AA. Plasma cell-free DNA profiling of PTEN-PI3K-AKT pathway aberrations in metastatic castration-resistant prostate cancer. *JCO Precis Oncol* 2021;5:PO.20.00424. PMID [34250422](#)
9. **Kwan EM**, Fettke H, Crumbaker M, Docanto MM, To SQ, Bukczynska P, Mant A, Ng N, Foroughi S, Graham LK, Haynes A, Azer S, Lim LE, Segelov E, Mahon K, Davis ID, Parente P, Pezaro C, Todenhoffer T, Sathianathan N, Hauser C, Horvath LG, Joshua AM, Azad AA. Whole blood GRHL2 expression as a prognostic biomarker in metastatic hormone-sensitive and castration-resistant prostate cancer. *Transl Androl Urol* 2021;10(4):1688-1699. PMID [33968657](#)
10. **Kwan EM**, Fettke H, Docanto MM, To SQ, Bukczynska P, Mant A, Pook D, Ng N, Graham LK, Mangiola S, Segelov E, Mahon K, Davis ID, Parente P, Pezaro C, Todenhoffer T, Horvath LG, Azad AA. Prognostic utility of a whole blood androgen receptor-based gene signature in metastatic castration-resistant prostate cancer. *Eur Urol Focus* 2021;7(1):63-70. PMID [31103601](#)
11. Davies A, Foo M, Gan CL, Kourambas J, Redgrave N, Donnellan S, Appu S, Williams S, Coleman A, Segelov E, Bradley J, Soo G, Ramdave S, **Kwan EM***, Azad AA*. ⁶⁸Ga-prostate specific membrane antigen (PSMA) PET/CT as a clinical decision-making tool in biochemically recurrent prostate cancer. *Asia Pac J Clin Oncol* 2021;18(5):e204-e210. PMID [34161628](#) *Co-senior author
12. Fettke H*, **Kwan EM***, Docanto MM, Bukczynska P, Ng N, Graham LK, Mahon K, Hauser C, Tan W, Wang XH, Zhao Z, Zheng T, Zhou K, Du P, Yu J, Yong H, Jia S, Kohli M, Horvath LG, Azad AA. Combined cell-free DNA and RNA profiling of the androgen receptor: clinical utility of a novel multi-analyte liquid biopsy assay for metastatic prostate cancer. *Eur Urol* 2020;78(2):173-180.
* Co-first author PMID [32487321](#)
13. **Kwan EM**, Azad AA. Chemotherapy, not AR-targeted therapy should be used upfront for metastatic hormone-sensitive prostate cancer (mHSPC). PRO: Docetaxel chemotherapy should be the default consideration in mHSPC. *Curr Opin Urol* 2020;30(4):617-619. PMID [32452996](#)

14. **Kwan EM**, Thangasamy IA, Teh J, Alghazo O, Sathianathan NJ, Lawrentschuk N, Azad AA. Navigating systemic therapy for metastatic castration-naïve prostate cancer. *World J Urol* 2019. doi: 10.1007/s00345-019-03060-7. PMID [31897602](#)
15. **Kwan EM**, Semira MC, Bergin ART, Muttiah C, Beck S, Anton A, Campbell D, Wong S, Rosenthal M, Gibbs P, Tran B. Impact of access to novel therapies on the initial management of castrate-resistant prostate cancer: an Australian multicentre study. *Intern Med J* 2019;49(11):1378-1385. PMID [30779277](#)
16. Fettke H*, **Kwan EM***, Azad AA. Cell-free DNA in cancer: current insights. *Cell Oncol (Dordr)* 2019;42(1):13-28. PMID [30367445](#) * Co-first author
17. To SQ*, **Kwan EM***, Fettke HC, Mant A, Docanto MM, Martelotto L, Bukczynska P, Ng N, Graham LK, Parente P, Pezaro C, Mahon K, Horvath L, Todenhof T, Azad AA. Expression of androgen receptor splice variant 7 or 9 in whole blood does not predict response to androgen-axis-targeting agents in metastatic castration-resistant prostate cancer. *Eur Urol* 2018;73(6):818-821. PMID [29398263](#) * Co-first author
18. **Kwan EM**, Beck S, Amir E, Jewett MA, Sturgeon JFG, Anson-Cartwright L, Chung PWM, Warde PR, Moore MJ, Bedar PL, Tran B. Impact of granulocyte-colony stimulating factor on bleomycin-induced pneumonitis in chemotherapy-treated germ cell tumours. *Clin Genitourin Cancer* 2017;S1558-7673(17)30267-7. PMID [28943331](#)
19. **Kwan E**, Houli N, Pitcher M, Wong S. Appendiceal metastasis in a patient with advanced breast cancer on hormonal therapy. *Int J Cancer Clin Res* 2016;3(5):059. doi: [10.23937/2378-3419/3/3/1059](#)

Co-author publications (ordered by recency):

20. Parekh K, van der Zande K, Ng SWS, Herberts C, **Kwan EM**, Vandekerckhove G, van der Noort V, Busard MPH, Beeker A, van den Berg P, de Feijter JM, Dezentje V, Hamberg P, Houtsma D, Ras S, Tascilar M, Tutuhatunewa-Louhanepessy RD, Liao YJ, Tolmeijer SH, Donnellan G, Chi KN, Wyatt AW, Zwart W, Bergman AM. Cabazitaxel versus abiraterone or enzalutamide for poor-prognosis metastatic castration-resistant prostate cancer after docetaxel: A phase 2 trial with a circulating tumor DNA analysis. *Eur Urol Oncol* 2025:S2588-9311(25)00198-1. PMID [41033927](#)
21. Werneck Gomes H, Lister NL, Keerthikumar S, Niranjan B, Richards M, Ryan A, **Kwan EM**, Risbridger GP, Taylor RA. p-AKT protein expression predicts response to AKT inhibitor combined with docetaxel therapy in adenocarcinoma and neuroendocrine prostate cancer. *Clin Cancer Res* 2025;31:2727-2740. PMID [40277461](#)
22. Jewell KE, Buteau JP, Medhurst E, **Kwan EM**, Sandhu S, Azad AA, Hofman MS. Safety and efficacy of 20 cycles of [¹⁷⁷Lu] Lu-PSMA-617 for metastatic castration-resistant prostate cancer. *J Nucl Med* 2025:jnumed.124.269447. PMID [40081956](#)
23. Eifer M, Sutherland DEK, Goncalves I, Buteau JP, Au L, Azad AA, Emmett L, Kong G, Kostos L, Ravi Kumar AS, **Kwan EM**, Medhurst E, Sandhu S, Tran B, Wyatt AA, Hofman MS. Therapy-related myeloid

neoplasms following Lutetium-177 [177Lu]Lu-PSMA therapy in patients with metastatic castration-resistant prostate cancer: a case series. *J Nucl Med* 2025;jnumed.124.268640. PMID [39978813](#)

24. Davis ID, Anton A, **Kwan EM**. ...but words will never hurt me. *Eur Urol* 2025;87(3):289-291. PMID [39799040](#)
25. Fonseca NM, Maurice-Dror C, Herberts C, Tu W, Fan W, Murtha AJ, Kollmannsberger C, **Kwan EM**, Parekh K, Schonlau E, Bernales CQ, Donnellan G, Ng SWS, Sumiyoshi T, Vergidis J, Noonan K, Finch DL, Zulfiqar M, Miller S, Parimi S, Lavoie J, Hard E, Soleimani M, Nappi L, Eigl BJ, Kollmannsberger C, Taavitsainen S, Nykter M, Tolmeijer S, Boerrigter E, Mehra N, van Erp NP, De Laere B, Linderg J, Gronberg H, Khalaf DJ, Annala M, Chi KN, Wyatt AW. Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer. *Nat Commun* 2024;15(1):1828. PMID [38418825](#)
26. Hofman MS, Emmett L, Sandhu S, Iravani A, Buteau JP, Joshua AM, Goh JC, Pattison DA, Tan TH, Kirkwood ID, Ng S, Francis RJ, Gedy C, Rutherford NK, Weickhardt A, Scott AM, Lee S, **Kwan EM**, Azad AA, Ramdave S, Redfern AD, MacDonald W, Guminski A, Hsiao E, Chua W, Lin P, Zhang AY, Stockler MR, Williams SG, Martin AM, Davis ID. Overall survival with [¹⁷⁷Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial. *Lancet Oncol* 2024;25:99-107. PMID [38043558](#)
27. Warner EW, Van der Eecken K, Murtha AJ, **Kwan EM**, Herberts C, Sipola J, Ng SWS, Chen XE, Fonseca NM, Ritch E, Schonlau E, Bernales CQ, Donnellan G, Munzur AD, Parekh K, Beja K, Wong A, Verbeke S, Lumen N, Van Dorpe J, De Laere B, Annala M, Vandekerckhove G, Ost P, Wyatt AW. Multi-region sampling of de novo metastatic prostate cancer reveals complex polyclonality and enables accurate clinical genotyping. *Nat Cancer* 2023;5:114-130. PMID [38177459](#)
28. Fettke H, Dai C, **Kwan EM**, Zheng T, Du P, Ng N, Bukczynska P, Docanto M, Kostos L, Foroughi S, Brown S, Graham LK, Mahon K, Horvath LG, Jia S, Kohli M, Azad AA. BRCA-deficient metastatic prostate cancer has an adverse prognosis and distinct genomic phenotype. *EBioMedicine* 2023;95:104738. PMID [37549632](#)
29. Kostos L, Fettke H, Kwan EM, Azad AA. Utility and clinical application of circulating tumor DNA (ctDNA) in advanced prostate cancer. *Société Internationale d'Urologie Journal* 2023;4(4):273-286.
30. Fang S, Kohli M, Zhe S, Lin HM, Azad AA, Fettke H, **Kwan EM**, Horvath LG, Mak B, Zhen T, Du P, Jia S, Kirby RM. Multi-Omic Integration of Blood-Based Tumor Associated Genomic and Lipidomic Profiles Using Machine Learning Models in Metastatic Prostate Cancer. *JCO Clin Cancer Inform* 2023;e2300057. PMID [37490642](#)
31. Tolmeijer SH, Boerrigter E, Sumiyoshi T, **Kwan EM**, Ng SWS, Annala M, Donnellan G, Herberts C, Benoist GE, Hamberg P, Somford DM, van Oort IM, Schalken JA, Mehra N, van Erp NP, Wyatt AA. Early

on-treatment changes in circulating tumor DNA fraction and response to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer. *Clin Cancer Res* 2023; 29(15):2835-2844. PMID [36996325](#)

32. Ritch EJ, Herberts C, Warner EW, Ng SWS, **Kwan EM**, Bacon JVW, Bernales CQ, Schönlau E, Fonseca NM, Giri VN, Maurice-Dror C, Vandekerckhove G, Jones SJM, Chi KN, Wyatt AW. A generalizable machine learning framework for classifying DNA repair defects using ctDNA exomes. *NPJ Precis Oncol* 2023;13;7(1):27. PMID [36914848](#)
33. Pereira-Salgada A, Anton A, **Kwan EM**, Franchini F, Mahar RK, Tran B, IJzerman M. Real-world clinical outcomes and cost estimates of metastatic castration-resistant prostate cancer treatment: does sequencing of taxanes and androgen receptor targeted agents matter? *Expert Rev Pharmacoecon Outcomes Res* 2022;1-9. PMID [36541133](#)
34. Kelly R, Jensen A, Karunaratna N, Wong S, Shapiro J, Weickhardt A, Parente P, Azad AA, Uccellini A, Torres J, Parnis F, Goh J, **Kwan EM**, Brown S, Steer C, Warren M, Gibbs P, Tran B, Anton A. PSMA PET-CT use prior to systemic therapy in metastatic castration-resistant prostate cancer. *BJU Int* 2022. doi: 10.1111/bju.15930. PMID [36371671](#)
35. Fizazi K, Retz M, Petrylak DP, Goh JC, Perez-Gracia JL, Lacombe L, Zschabitz S, Burotto M, Mahammed H, Gravis G, Bastos DA, McCune SL, Vazquez Limon JC, **Kwan EM**, Castellano D, Flechon A, Saad F, Grimm M, Shaffer DR, Armstrong AJ, Bhagavatheeswaran P, Amin NP, Unsal-Kacmaz K, Wang X, Li J, Loehr A, Pachynski RK. Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial. *J Immunother Cancer* 2022;10(8):e004761. PMID [35977756](#)
36. Mak B, Lin HM, **Kwan EM**, Fettke H, Tran B, Davis ID, Mahon K, Stockler MR, Briscoe K, Marx G, Zhang A, Crumbaker M, Tan W, Huynh K, Meikle TG, Mellett NA, Hoy AJ, Du P, Yu J, Jia S, Joshua AM, Waugh DJ, Butler LM, Kohli M, Meikle PJ, Azad AA, Horvath LG. Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer. *BMC Med* 2022;20(1):112. PMID [35331214](#)
37. Anton A, Pillai S, Semira MC, Wong S, Shapiro J, Weickhardt A, Azad A, **Kwan EM**, Spain L, Gunjur A, Torres J, Parente P, Parnis F, Goh J, Baenziger O, Gibbs P, Tran B. Real-world first-line systemic therapy patterns in metastatic castration-resistant prostate cancer. *BJUI Compass* 2021; 3(3):205-213. PMID [35492221](#)
38. Chazan G, Anton A, Wong S, Shapiro J, Weickhardt A, Azad A, **Kwan EM**, Spain L, Gunjur A, Torres J, Parente P, Parnis F, Goh J, Gibbs P, Tran B. Beyond cabazitaxel: late line treatments in metastatic castration-resistant prostate cancer: a retrospective multi-centre analysis. *Asia Pac J Clin Oncol* 2022. doi: 10.1111/ajco.13732. PMID [35098653](#)

39. Kolinsky MP, Niederhoffer KY, **Kwan EM**, Wyatt AW, Hotte SJ, Hamilou Z, Yip SM, Chi KN, Saad F. Considerations on the identification and management of metastatic prostate cancer patients with DNA repair gene alterations in the Canadian context. *Can Urol Assoc J* 2022;16(4):132-143. PMID [34812730](#)
40. Van der Eecken K, Vanwelkenhuyzen J, Deek MP, Tran PT, Warner E, Wyatt AW, **Kwan EM**, Verbeke S, Van Dorpe J, Fonteyne V, Lumen N, De Laere B, Ost P. Tissue- and blood-derived genomic biomarkers for metastatic hormone-sensitive prostate cancer: a systemic review. *Eur Urol Oncol* 2021;4(6):914-923. PMID [34801437](#)
41. Lin HM, Yeung N, Mak B, Huynh K, Meikle T, Mellett N, **Kwan EM**, Fettke H, Tran B, Davis ID, Mahon KL, Zhang A, Stockler M, Briscoe K, Marx G, Crumbaker M, Du P, Yu J, Jia S, Joshua AM, Azad AA, Butler LM, Meikle PJ, Horvath LG. Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase. *EBioMedicine* 2021;72:103625. PMID [34656931](#)
42. Lin HM, Yeung N, Hastings JF, Croucher DR, Huynh K, Meikle TG, Mellett NA, **Kwan EM**, Davis ID, Tran B, Mahon KL, Zhang A, Stockler MR, Briscoe K, Marx G, Bastick P, Crumbaker ML, Joshua AM, Azad AA, Meikle PJ, Horvath LG. Relationship between circulating lipids and cytokines in metastatic castration-resistant prostate cancer. *Cancers (Basal)* 2021;13(19):4964. PMID [34638448](#)
43. Risbridger G, Clark A, Porter L, Toivanen R, Bakshi A, Lister N, Pook D, Pezaro C, Sandhu S, Keerthikumar S, Quezada Urban R, Papargiris M, Kraska J, Madsen H, Wang H, Richards M, Nirajan B, O'Dea S, Teng L, Wheelahan W, Li Z, Choo N, Ouyang J, Thorne H, Devereux L, Hicks R, Sengupta S, Harewood L, Iddawala M, Azad AA, Goad J, Grummet J, Kourambas J, **Kwan EM**, Moon D, Murphy D, Pderesen J, Clouston D, Norden S, Ryan A, Furic L, Goode D, Frydenberg M, Lawrence M, Taylor R. The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology. *Nat Commun* 2021;12(1):5049. PMID [34413304](#)
44. Fettke H, **Kwan EM**, Bukczynska P, Steen JA, Docanto M, Ng N, Parente P, Mant A, Foroughi S, Pezaro C, Hauser C, Guyen-Dumont T, Southey MC, Azad AA. Independent prognostic impact of plasma NCOA2 alterations in metastatic castration-resistant prostate cancer. *The Prostate* 2021;81(13):992-1001. PMID [34254334](#)
45. Pathmanandavel S, Crumbaker M, Yam AO, Nguyen A, Rofe C, Hovey E, Gedye C, **Kwan EM**, Hauser C, Azad AA, Eu P, Joshua AM, Martin AJ, Emmett L. ¹⁷⁷Lutetium-PSMA-617 and idronoxil in men with end-stage metastatic castration-resistant prostate cancer: patient outcomes and predictors of treatment response of a phase I/II trial. *J Nucl Med* 2021;63(4):560-566. PMID [34326127](#)
46. Anton A, Wong S, Shapiro J, Weickhardt A, Azad AA, **Kwan EM**, Spain L, Gunjur A, Torres J, Parente P, Parnis F, Goh J, Semira C, Gibbs P, Tran B, Pezaro C. Real-world incidence of significant skeletal events and bone modifying agent use in castration-resistant prostate cancer – an Australian multi-centre observational study. *Eur J Cancer* 2021;157:485-492. PMID [34344533](#)

47. Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, Pattison DA, Tan TH, Kirkwood ID, Ng S, Francis RJ, Gedye C, Rutherford NK, Weickhardt A, Scott AM, Lee S, **Kwan EM**, Azad AA, Ramdave S, Redfern AD, MacDonald W, Guminski A, Hsiao E, Chua W, Lin P, Zhang AY, McJannett MM, Stockler MR, Violet JA, Williams SG, Martin AJ, Davis ID. ¹⁷⁷Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer: a randomised, open-label, phase 2 trial. *Lancet* 2021;397(10276):797-804. PMID [33581798](#)
48. Kelly R, Anton A, Wong S, Shapiro J, Weickhardt A, Azad AA, **Kwan EM**, Spain L, Muthusamy A, Torres J, Parente P, Parnis F, Goh J, Joshua AM, Pook D, Baenziger O, Gibbs P, Tran B. Real-world use of first-generation anti-androgens: impact on outcomes and subsequent therapies in metastatic castration-resistant prostate cancer. *BJU International* 2021; 128 Suppl 1:18-26. PMID [34622543](#)
49. Fankhauser CD, Tran B, Pedregal M, Ruiz-Morales JM , Gonzalez-Billalabeitia E , Patrikidou A , Amir E, Seidel C , Bokemeyer C, Hermanns T, Tryakin A, Rumyantsev A, Brito M, Flechon A, **Kwan EM**, Cheng T, Castellano D, Garcia Del Muro X, Hamid AA, Ottaviano M, Palmieri G, Kitson R, Reid A , Heng DYC, Bedard PL, Sweeney CJ, Connors JM. A risk benefit analysis of prophylactic anticoagulation for patients with metastatic germ cell tumours undergoing first-line chemotherapy. *Eur Urol Focus* 2020;7(5):1130-1136. PMID [33032968](#)
50. Lau E, McCoy P, Reeves F, Chow K, Clarkson M, **Kwan EM**, Packwood K, Northen H, He M, Kingsbury Z, Mangiola S, Kerger M, Furrer MA, Crowe H, Costello AJ, McBride DJ, Ross MT, Pope B, Hovens CM, Corcoran N. Detection of ctDNA in Plasma of Patients with Clinically Localised Prostate Cancer is Associated with Rapid Disease Progression. *Genome Med* 2020;17;12(1):72. PMID [32807235](#)
51. Crumbaker M, Pathmanandavel S, Yam AO, Nguyen A, Ho B, Chan L, Ende J, Rofe C, Kamonwana K, **Kwan EM**, Azad AA, Sharma S, Keane J, Eu P, Joshua AM, Emmett L. Phase I/II trial of combination ¹⁷⁷Lutetium PSMA-617 and idronoxil (NOX66) in men with end-stage metastatic castration-resistant prostate cancer (LuPIN). *Eur Urol Oncol* 2020;4(6):963-970. PMID [32758400](#)
52. Fettke H, **Kwan EM**, Bukczynska P, Ng N, Nguyen-Dumont T, Southey M, Davis ID, Mant A, Parente P, Hauser C, Azad AA. Prognostic impact of plasma cell-free DNA concentration in androgen receptor pathway inhibitor-treated metastatic castration-resistant prostate cancer. *Eur Urol Focus* 2020;4(6):963-970. PMID [32739405](#)
53. Schmidt A, Anton A, Shapiro J, Wong S, Azad A, **Kwan EM**, Spain L, Muthusamy A, Torres J, Parente P, Parnis F, Goh J, Joshua A, Pook D, Gibbs P, Tran B, Weickhardt A. Treatment outcomes for patients with metastatic castrate-resistant prostate cancer following docetaxel for hormone sensitive disease. *Asia Pac J Clin Oncol* 2021;17(1):36-42. PMID [32970925](#)
54. Fettke H, Steen J, **Kwan EM**, Bukczynska P, Keerthikumar S, Goode D, Docanto M, Ng N, Martelotto L, Hauser C, Southey M, Azad AA, Nguyen-Dumont T. Analytical validation of an error-corrected next-

generation sequencing assay for ultra-sensitive ctDNA profiling. *Biotechniques* 2020;69(2):133-140. PMID [32654508](#)

55. Pereira-Salgado A, **Kwan EM**, Tran B, Gibbs P, De Bono J, IJzerman MJ. Systematic Review of Efficacy and Health Economic Implications of Real-world Treatment Sequencing in Prostate Cancer: Where Do the Newer Agents Enzalutamide and Abiraterone Fit in? *Eur Urol Focus* 2020;7(4):752-763. PMID [32273196](#)
56. Kohli M, Tan W, Zheng T, Wang A, Montesinos C, Wong C, Du P, Ji S, Yadav S, Horvath LG, Mahon K, **Kwan EM**, Fettke H, Yu J, Azad AA. Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer. *EBioMedicine* 2020;54:102728. PMID [32268276](#)
57. Thangasamy IA, **Kwan EM**, Teh J, Sathianathan N, Alghazo O, Siva S, Azad A, Murphy DG. Novel agents for metastatic hormone-sensitive prostate cancer – A practice guide for urologists. *BJU Int* 2019;125(3):342-345. PMID [31660679](#)
58. Tran B, Ruiz-Morales JM, Gonzalez-Billalabeitia E, Patrikidou A, Amir E, Seidel C, Bokemeyer C, Fankhauser C, Hermanns T, Rumyantsev A, Tryakin A, Brito M, Flechon A, **Kwan EM**, Cheng T, Castellano D, Del Muro XG, Hamid A, Ottaviano M, Palmieri G, Kitson R, Reid A, Heng DY, Bedard PL. Large Retroperitoneal Lymphadenopathy and Increased Risk of Venous Thromboembolism in Patients receiving First Line Chemotherapy for Metastatic Germ Cell Tumours: A Study by The Global Germ Cell Cancer Group (G3). *Cancer Med* 2019. doi: 10.1002/cam4.2674. PMID [31715650](#)
59. Lee CK, Scott C, Lindeman GJ, Hamilton A, Lieschke E, Gibbs E, Asher R, Badger H, Paterson R, Macnab L, **Kwan EM**, Francis P, Boyle F, Friedlander M. Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer. *Br J Cancer* 2019;120(3):279-285. PMID [30655615](#)
60. Ha FJ, Spain L, Dowling A, **Kwan EM**, Pezaro C, Day D, Chia PL, Tran B, Pook D, Weickhardt AJ. Timing of Brain Metastases Development in Metastatic Renal Cell Cancer patients treated with Targeted Therapies and Survival Outcomes: an Australian Multicentre Study. *Asia Pac J Clin Oncol* 2019;15(5):e97-e102. PMID [30701671](#)
61. Lam M, Tran B, Beck S, Tie J, Herath D, Whittle J, **Kwan E**, Fox S, Fellowes A, Ananda S, Lipton L, Gibbs P, Rosenthal M, Desai J. Precision medicine using a clinician-directed, tailored approach to molecular profiling. *Asia Pac J Clin Oncol* 2018;14(1):84-90. PMID [28943331](#)
62. Day D, Kanjanapan Y, **Kwan E**, Yip D, Lawrentschuk N, Davis ID, Azad A, Wong S, Rosenthal M, Gibbs P, Tran B. Benefit from cytoreductive nephrectomy and the prognostic role of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma. *Intern Med J*. 2016;46(11):1291-1297. PMID [27507629](#)

63. Dai D, Kanjanapan Y, **Kwan E**, Yip D, Lawrentschuk N, Andrews M, Davis ID, Azad A, Rosenthal M, Wong S, Arifeen S, Alam M, Gibbs P, Tran B. Patterns of care for metastatic renal cell carcinoma in Australia. *BJU Int* 2015;116 Suppl 3:36-41. PMID [27507629](#)
64. Jayasinghe SR, Mishra A, van Daal A, **Kwan E**. Genetics in cardiovascular disease: Design and development of a DNA Biobank. *Exp Clin Cardiol* 2009;14(3):33-37. PMID [20098575](#)

HONOURS & AWARDS		
Year	Award / Prize	Total Value
2026	North Eastern Melbourne Integrated Cancer Service (NEMICS) Professional Development Grant	AUD \$4,500
2026	Monash Partners and Equity Trustees STAR Clinical Fellowship	AUD \$120,000
2025	Monash Partners EMCR Excellence Award – Novel Use of Data category	N/A
2025	MOGA-elected National Representative Speaker, ESMO Asia Congress 2025 (Liquid Biopsy Global Perspectives session)	N/A
2025	Delegate, ESMO 2025-2026 Global Leadership Programme (worldwide selection; 16 participants)	N/A
2025	Finalist, Victorian Premier's Awards for Health and Medical Research	N/A
2024	Conquer Cancer Foundation ASCO Nizar M. Tannir, MD, Endowed Merit Award (highest scoring abstract in Genitourinary Cancers) 'Circulating tumour DNA fraction as a predictor of treatment efficacy in a randomized phase 2 trial of 177Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer progressing after docetaxel (TheraP ANZUP 1603)	USD \$1,000
2024	Conquer Cancer Foundation ASCO Genitourinary Cancers Symposium Merit Award <i>'Impact of androgen deprivation therapy on circulating tumor DNA detection in de novo metastatic castration-sensitive prostate cancer'</i>	USD \$1,000
2022	University of British Columbia Science Co-op Supervisor Recognition Award for Mr Wilson Tu (see Supervision section below)	N/A
2022	British Journal of Urology International (BJUI) Reviewer of the Month	N/A
2021	Delegate (competitive selection), Medical Oncology Group of Australia (MOGA) Oncology Professionals Advancing Leadership Program	N/A
2020	Monash University Postgraduate Publications Award	AUD \$5,000
2019	ANZUP Scholarship to attend Dana Farber Cancer Institute Prostate Cancer Masterclass	AUD \$15,000
2018	Astellas Young Investigator of the Year Award	AUD \$10,000
2018	Conquer Cancer Foundation ASCO Genitourinary Cancers Symposium Merit Award <i>'Whole blood AR-V7 and AR-V9 mRNA expression and treatment response in metastatic castrate-resistant prostate cancer'</i>	USD \$1,000
2018	Scholarship to attend ANZUP Annual Scientific Meeting	AUD \$750
2018	Delegate (competitive selection), Australia & Asia Pacific Clinical Oncology Research Development (ACORD) Protocol Development Workshop	AUD \$2,000
2015	Best Poster Presentation, Western Health Research Week	N/A

'Review of an innovative health service approach, the Symptom Urgent Review Clinic, to improve efficiency and quality of care for breast cancer patients receiving adjuvant chemotherapy'

2014	Scholarship to attend ANZUP Annual Scientific Meeting	AUD \$750
2010	Finalist for Victorian Junior Doctor of the Year Award, Confederation of Postgraduate Medical Education Councils (CPMEC)	N/A
2009	Dux of Elective/Specialty Clinical Rotations, Bond University	N/A
2008	Dux of Core Clinical Rotations, Bond University	N/A

PROFESSIONAL SERVICE AND LEADERSHIP

Direct Supervision / Manager

- Dr Harriet Herbison, Monash University, PhD student, 2025 –
- Dr Nadia Hitchen, WEHI, Clinical Research Fellow, 2025 –
 - Best Fellow Award, ANZUP Annual Scientific Meeting, Melbourne, Australia, 2025.
- Mr Wilson Tu, University of British Columbia, Co-op student, 2022 – 2024
 - Best Basic Science Prize, Lorne D. Sullivan Research Day, Vancouver, Canada, 2022.
- Dr Andrea Knox, Peter MacCallum Cancer Centre, Medical Oncology Trainee, 2021.
 - Oral Presentation, ANZUP Annual Scientific Meeting, Adelaide, July 2021.
- Dr Amy Davies, Monash Health, Medical Oncology Trainee, 2020.
 - 2 x publications (Crit Rev Oncog, Asia Pac J Clin Oncol)
- BC Cancer Genitourinary Biobank Data Collectors
 - Dr Elsa Sartori-Muller, Oct 2022 – Oct 2024
 - Ms Vivian Gusmao, Apr 2024 – Oct 2024
 - Ms Anna Riminchan, Apr 2023 – Oct 2024
 - Mr Danny Liu, Oct 2023 – Oct 2024
 - Ms Megan Hew, Apr 2023 – Oct 2024
 - Ms Parveen Dhillon Randhawa, Oct 2023 – Oct 2024
 - Ms Ariel Park, Oct 2023 – July 2024
 - Ms Jaidyn Miguel, Apr 2023 – July 2024
 - Ms Tate Zingle, Apr 2023 – May 2024
 - Dr Yomna Hamid, Oct 2022 – Apr 2024
 - Ms Natassja Eogl, Apr 2023 – Oct 2023
 - Mr William Stubbs, Oct 2022 – Sep 2023
 - Ms Evalyn Black, May 2022 – Aug 2022
 - Ms Kristen Yoo, May 2022 – Aug 2022

Journal Reviewer

- BMC Cancer (1), 2025 –
- Therapeutic Advances in Medical Oncology (Editorial Reviewer Board), 2023 –
- The Prostate (1), 2023 –

- Clinical & Experimental Metastasis (1), 2023 –
- European Urology Focus (2), 2022 –

- JCO Precision Oncology (2), 2022 –
- Lancet Oncology (1), 2022 –
- Cancer Research Communications (2), 2022 –
- Scientific Reports (1), 2021 –
- British Journal of Urology International (7), 2020 –
- Journal of Global Oncology (2), 2018 –

Faculty Participation

- Faculty Keynote Speaker, Thomas Ashworth CTC and Liquid Biopsy Symposium, Sydney, 2025
- Faculty Speaker, Astellas Global Prostate Cancer Masterclass, Lisbon, Portugal, 2025
- Chair, Masterclass – Advanced Prostate Cancer, Australian & New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) Annual Scientific Meeting, Melbourne, 2025
- Panellist, Reading with the Experts: Prostate Cancer Case Studies, Australian and New Zealand Society of Nuclear Medicine (ANZSNM) Annual Scientific Meeting, Melbourne, 2025
- Session Chair and Expert Panel, Immuno-oncology in GU malignancies symposium, Victorian Comprehensive Cancer Centre Session Chair, Melbourne, 2020
- Faculty, University of Melbourne Masters of Cancer Science: Cancer Research (MEDI90086)
- Steering Committee and Panel Chair, 8th Academy of Cancer Education (ACE 8) Asia-Pacific Prostate Cancer Conference, China, 2019.
- Expert Panel, Updates in Prostate Cancer, PROSPECT Education Meeting, Melbourne, 2018
- Session Chair, “Current ANZUP Clinical Trials”, ANZUP Annual Scientific Meeting, 2018

Committees

- ANZUP Annual Scientific Meeting Organising Committee, 2025 – Present
- Eastern Health Medical Oncology Morbidity and Mortality Committee Lead, 2024 – Present
- Eastern Health Medical Oncology Hand Hygiene Audit Lead, 2025 – Present
- PhD Committee Panel Member – Mr Xielin Huang, 2025 – Present
- PhD Committee Milestone Panel Member – Dr Henry Yao (5 Feb 2025)
- Research Masters Committee Panel Member – Dr Abram Botros (20 Dec 2024)
- Melbourne Urological Research Alliance (MURAL) Prostate Oncology Working Committee, 2019 –
- Breast Cancer Chemotherapy Protocol Committee, eviQ Cancer Treatments Online,
- President of Victorian Medical Oncology Training Group (VMOTG), 2016 – 2017
- Breast Cancer Chemotherapy Protocol Committee, eviQ Cancer Treatments Online, 2016 – 2017
- Postgraduate Medical Council of Victoria Executive Committee (Welfare Division), 2014 – 2015
- Royal Melbourne Hospital Morbidity and Mortality Committee, 2011 – 2014
- Royal Melbourne Hospital Junior Medical Officer Education Committee, 2010 – 2011
- Junior Research Coordinator, Cardiology Department, Gold Coast Hospital, 2006 – 2009

Professional Membership

- Royal Australian College of Physicians, 2017 –
- American Society of Clinical Oncology (ASCO), 2014 –
- Australian & New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP), 2014 –
- Medical Oncology Group of Australia (MOGA), 2014 –

CLINICAL TRIALS EXPERIENCE

Site Principal Investigator – Investigator-led and cooperative group trials

- A randomised phase 2 trial of 177Lu-PSMA617 theranostic versus cabazitaxel in progressive metastatic castration resistant prostate cancer (TheraP). Monash Health, Melbourne, Australia 2018-2020 (NCT03392428)
- A phase II study of Avelumab + stereotactic ablative body radiosurgery for metastatic castration-resistant prostate cancer. 2018-2020 (ACTRN12618000954224)
- Electronic Castrate-Resistant Prostate Cancer Australian Database Clinical Registry (ePAD). Monash Health, Melbourne, Australia. 2018-2020 (ACTRN12616000585426)
- Clinical utility of PSMA PET/CT in two distinct patient cohorts: biochemical recurrence after radical treatment, and non-metastatic castrate-resistant prostate cancer. Monash Health, Melbourne, Australia. 2017-2020

Site Principal Investigator – Sponsored clinical trials

- A phase II, randomized, multicentre study of cabazitaxel versus abiraterone or enzalutamide in poor prognosis-metastatic castration-resistant prostate cancer (OZM-054). Monash Health, Melbourne, Australia. 2018-2020 (NCT02254785)
- A phase II study of nivolumab in combination with either rucaparib, docetaxel, or enzalutamide in men with castration-resistant metastatic prostate cancer (CheckMate9KD). Monash Health, Melbourne, Australia. 2018-2020 (NCT03338790)
- A multinational, Phase 3, randomized, double-blind, placebo-controlled efficacy and safety study of enzalutamide plus androgen deprivation therapy (ADT) versus placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer (ARCHES). Monash Health, Melbourne, Australia. 2018-2020 (NCT02677896)
- A phase II, open-Label, 2-arm, response rate study of talazoparib in men with DNA repair defects and metastatic castration-resistant prostate cancer (TALAPRO-1). Monash Health, Melbourne, Australia. 2018-2020 (NCT03148795)
- A phase III, open label, randomised study to assess the efficacy and safety of olaparib versus enzalutamide or abiraterone in men with metastatic castration-resistant prostate cancer (PROFOUND). Monash Health, Melbourne, Australia. 2018-2020 (NCT02987543)
- A phase I multicentre, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of MEDI9447 alone and in combination with MEDI4736 in adult subjects with select advanced solid tumours. Monash Health, Melbourne, Australia. 2018-2020 (NCT02503774)

PRESENTATIONS

Invited Presentations

1. From plasma to practice: Liquid biopsy for personalising PSMA radioligand therapy in metastatic prostate cancer, Thomas Ashworth CTC and Liquid Biopsy Symposium – Keynote Speaker, Sydney, Australia, 29 October 2025
2. Circulating tumour DNA genomic correlates in mCRPC treated with LuPSMA or cabazitaxel from the randomised phase II TheraP trial (ANZUP 1603), Prostate Cancer Foundation Retreat, Carlsbad, California, USA, 25 October 2025
3. Scoring with Confidence: Practical Heuristics for Grant Review as a Young Investigator, Prostate Cancer Foundation Young Investigator Forum, Carlsbad, California, USA, 22 October 2025
4. Treatment of metastatic hormone-sensitive prostate cancer in the era of personalised medicine, Astellas Global Prostate Cancer Masterclass, Lisbon, Portugal, 4 October 2025
5. Somatic genomics in advanced prostate and bladder cancers, The Limbic – Precision Oncology Masterclass (Online), 26 August 2025 [[Video Link](#)]
6. ASCO 2025 Updates: Genitourinary Cancers, The Limbic – ASCO Direct Game Changers, Melbourne, Australia, 17 June 2025 [[Video Link](#)]
7. How Genomics Is Changing the Way We Treat Advanced Prostate Cancer, Prostate Cancer Foundation Australia Annual Nursing Education Symposium, Sydney, Australia, 19 July 2025
8. Circulating tumour DNA to guide Lutetium-177-PSMA radioligand therapy in advanced prostate cancer: insights from the Australian TheraP clinical trial, Cell Signalling and its Therapeutic Implications, Melbourne, Australia, 14 May 2025
9. [¹⁷⁷Lu]Lu-PSMA-617 or cabazitaxel in metastatic prostate cancer: ctDNA analysis of the randomised phase 2 TheraP trial, Prostate Cancer Foundation & ProstIC global webinar (Online), April 2025 [[Video Link](#)]
10. ctDNA fraction predicts response to Lutetium PSMA in TheraP trial for metastatic castration-resistant prostate cancer, interview with Dr Andrea Miyahara from UroToday, Chicago, USA, June 2024 [[Video Link](#)]
11. The intersection between genomics and new therapies in advanced prostate cancer, Prostate Cancer Foundation Coast to Coast Support Group Meeting (Online), August 2024 [[Video Link](#)]
12. Plasma cfDNA to unravel biological insights of PSMA radioligand therapy, ProstIC Preceptorship 2024: Precision Oncology in Practice, Melbourne, Australia, March 2024 [[Video Link](#)]
13. Impact of androgen deprivation therapy on circulating tumour DNA detection in de novo metastatic castration-sensitive prostate cancer, DAVA Summit on GU Malignancies, Colorado Springs, USA, November 2023
14. Integrating ctDNA genotyping to guide treatment selection in prospective clinical trials: lessons from a nation-wide phase II umbrella study, ANZUP Annual Scientific Meeting, Melbourne, Australia, July 2023
15. Immunotherapy in bladder cancer, British Columbia Bladder Cancer Support Group, Vancouver, Canada, April 2023
16. Treatment advances in metastatic prostate cancer, Vancouver Prostate Cancer Support Group, Vancouver, Canada, May 2022

17. Circulating biomarkers in advanced prostate cancer, Asia-Pacific Prostate Cancer Conference, Melbourne, Australia, August 2019
18. What's new in advanced prostate cancer, Asia-Pacific Prostate Cancer Conference, Melbourne, Australia, August 2019
19. Immunotherapy in urological cancers, Victorian Urology Trainee Program, Melbourne, Australia, August 2019
20. Treatment individualisation for metastatic renal cell carcinoma, Ipsen Internal Meeting, Melbourne, Australia, July 2019
21. Phase I clinical trials: study design and biomarker integration, University of Melbourne Masters of Cancer Science: Cancer Research (MEDI90086), Melbourne, Australia, February 2019
22. Update on recent advances in prostate cancer treatment, Ringwood Prostate Cancer Patient Support Group, Melbourne, Australia, September 2018
23. Urological cancers update, Royal Australasian College of Physicians (RACP) Physician Education Program, Melbourne, Australia, July 2018
24. Androgen receptor variants: predictive and prognostic biomarkers in advanced prostate cancer, ANZUP Annual Scientific Meeting Translational Research Symposium, Sydney, Australia, July 2018
25. Advanced prostate cancer: how far we have come, Prostate Cancer Foundation of Australia (PCFA) Specialist Nurses Induction Program, Melbourne, Australia, October 2017
26. New therapeutic advances in metastatic renal carcinoma and metastatic urothelial carcinoma Clinical Oncology Society of Australia (COSA) Cancer Pharmacist Group, Melbourne, Australia, October 2017
27. The newly diagnosed advanced prostate cancer patient: STAMPEDE and LATITUDE, Urology Society of Australia and New Zealand (USANZ) Victorian State Meeting, Melbourne, Australia, October 2017
28. The changing face of advanced prostate cancer, Asia-Pacific Prostate Cancer Conference, Melbourne, Australia, August 2017
29. Medical Oncology in the FRACP Written Exam, Royal Australasian College of Physicians (RACP) Physician Education Program, Melbourne, Victoria, November 2017
30. Medical Oncology in the FRACP Written Exam, Royal Australasian College of Physicians (RACP) Physician Education Program, Melbourne, Victoria, November 2016
31. Upper tract urothelial carcinoma: a medical oncologist perspective, Urological Society of Australia and New Zealand (USANZ) Victorian Urology Surgical Program Melbourne, Australia, May 2016

Conference Presentations

32. Roberts HN, Liao YJR, Herberts C, Tolmeijer SH, Wang C, Riminchan A, Sartori-Muller E, Kwan EM, Annala M, Fonseca NM, Vergidis J, Noonan K, Finch DL, Zulfiqar M, Miller S, Vandekerkhove G, Wyatt AW, Maurice-Dror C, Chi KN. *Prostate cancer liver metastases: genomic profiling and clinical outcomes*, Poster Presentation, ASCO GU, 2025. San Francisco, USA.
33. Tolmeijer SH, Kwan EM, Ng SWS, Joshua AM, Emmett L, Crumbaker M, Hamid AA, Anton A, Horvath LG, Chan J, Bressel M, Buteau JP, Dhiantravan N, Ayati N, Keerthikumar S, Goode D, Ricks R, Hofman MS, Wyatt AW, Sandhu SK. *Circulating tumour DNA measurements and PET/CT imaging to evaluate response in a phase Ib trial of metastatic castration-resistant prostate cancer treated with Lutetium-177-PSMA-617 plus pembrolizumab*. Poster Presentation, ESMO Congress 2024. Barcelona, Spain.

34. **Kwan EM**, Hofman MS, Ng SWS, Emmett L, Sandhu S, Buteau JP, Iravani A, Joshua AM, Francis R, Subhash V, Lee S, Scott AM, Martin AJ, Stocker MR, Donnellan G, Annala A, Tolmeijer S, Azad AA, Davis ID, Wyatt AW. *Circulating tumour DNA fraction as a predictor of treatment efficacy in a randomized phase 2 trial of ¹⁷⁷Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603)*, Poster Presentation, ASCO Annual Meeting, 2024. Chicago, USA. * **Conquer Cancer Foundation Nizar M. Tannir Endowed Merit Award (highest scoring abstract in Genitourinary Cancers)**
35. **Kwan EM**, Murtha AJ, Tu W, Vasquez Rios C, Bernales CQ, Arviola SK, Donnellan G, Parekh K, Annala M, Maurice-Dror C, Vandekerckhove G, Chi KN, Wyatt AW. *Impact of androgen deprivation therapy (ADT) on circulating tumor DNA (ctDNA) detection in de novo metastatic castration-sensitive prostate cancer (mCSPC)*, Poster Presentation, ASCO GU, 2024. San Francisco, USA. * **Conquer Cancer Foundation Merit Award**
36. Munzur A, Sipola J, Seo C, **Kwan EM**, Parekh K, Bernales CQ, Donnellan G, Bloise I, Vandekerckhove G, Annala M, Maurice-Dror C, Chi KN, Herberts C, Takeda DY, Wyatt AW. *Chromatin modifications on plasma ctDNA as a tool to phenotype castration-resistant prostate cancer*, Poster Presentation, ASCO GU, 2024. San Francisco, USA.
37. **Kwan EM**, Rushton MK, Tu W, Hotte SJ, Mukherjee SD, Ong M, Kolinsky MP, Hamilou Z, Winquist E, Ferrario C, Marfarlane J, Saad F, Salim M, Jiang DM, Tu D, Hutchenreuther J, Annala M, Seymour L, Chi KN, Wyatt AW. *Prospective ctDNA genotyping for treatment selection in metastatic castration-resistant prostate cancer (mCRPC): The Canadian Cancer Trials Group phase II PC-BETS umbrella study*, Poster Presentation, ASCO GU, 2023. San Francisco, USA.
38. Pachynski RK, Iannotti N, Laccetti A, Carthon BC, Chi KN, Smith MR, Volgelzang NJ, Tu W, **Kwan EM**, Wyatt AW, Villaluna K, Yonginer B, Cesano A. *Oral EPI-7386 in patients with metastatic castration-resistant prostate cancer*, Poster Presentation, ASCO GU, 2023. San Francisco, USA.
39. Tolmeijer SH, Boerrigter E, Sumiyoshi T, Ng S, **Kwan EM**, Annala M, van Oort IM, Schalken JA, Van Erp NP, Wyatt AW, Mehra N. *On-treatment plasma ctDNA fraction and treatment outcomes in metastatic castration-resistant prostate cancer*, Poster Presentation, ASCO Annual Meeting, 2022. Chicago, USA.
40. Maurice-Dror C, Fonseca N, Herberts C, **Kwan EM**, Kollmannsberger C, Tu W, Khalaf DJ, Annala M, Schonlau E, Bernales CQ, Donnellan G, Vergidis J, Noonan K, Finch DL, Zulfiqar M, Stacy M, Wyatt AW, Chi KN. *Biallelic loss of TP53, PTEN, and RB1 in association to aggressive clinical features and poor outcomes in metastatic castration-resistant prostate cancer (mCRPC)*, Poster Presentation, ASCO Annual Meeting, 2022. Chicago, USA.
41. Warner E, Van der Eecken K, Murtha AJ, **Kwan EM**, Ng SW, Chen XE, Bernales CQ, Donnellan G, Schonlau E, Verbeke S, Lumen N, Van Drpe J, Vandekerckhove G, Ritch E, Annala M, De Laere B, Ost P,

Wyatt AW. *Multi-focal genomic dissection of synchronous primary and metastatic tissue from de novo metastatic prostate cancer*. Poster Presentation, AACR Annual Meeting, 2022. New Orleans, USA.

42. Knox A, Fettke H, Hauser C, Bukczynska P, Ng N, Foroughi S, Graham LK, Mahon KL, Tan W, Zheng T, Wang A, Dai C, Du P, Jia S, Horvath LG, Kohli M, Azad AA, **Kwan EM**. *Age-based assessment of cell-free DNA genomic profiles in metastatic castration-resistant prostate cancer (mCRPC)*, Poster Presentation, ASCO GU, 2022. San Francisco, USA.
43. Fettke H, Hauser C, **Kwan EM**, Dai C, Zheng T, Wang A, Tan W, Du P, Ng N, Bukczynska P, Foroughi S, Graham LK, Horvath LG, Mahon KL, Jia S, Kohli M, Azad AA. *Prognostic and predictive utility of DNA damage response (DDR) aberrations detected in cell-free DNA (cfDNA) in metastatic castration-resistant prostate cancer (mCRPC)*, Poster Presentation, ASCO GU, 2022. San Francisco, USA.
44. Xie O, Anton A, Zhong Y, Wong S, Shapiro J, Spain L, Arun A, **Kwan EM**, Weickhardt A, Gunjur A, Torres J, Parente P, Parnis F, Goh J, Brown S, Steer C, Gibbs P, Tran B. *Examining Real-World Prescribing Practices for Novel Antiandrogens in Metastatic Castration Resistant Prostate Cancer*, ANZUP Annual Scientific Meeting, 2021. Adelaide, Australia.
45. Petrylak DP, Perez-Gracia JL, Lacombe L, Bastos DA, Mahammedi H, **Kwan EM**, Zschabitz S, Armstrong AJ, Pachynski RK, Goh JC, Burotto M, Gravis G, McCune SL, Vazquez Limon JC, Retz M, Saad F, Amin NP, Li J, Unsal-Kacmaz K, Fizazi K. *CheckMate 9KD cohort A2 final analysis: Nivolumab (NIVO) + rucaparib for chemotherapy (CT)-naïve metastatic castration-resistant prostate cancer (mCRPC)*, Poster Presentation, ESMO Congress 2021. Lugano, Switzerland.
46. Lin HM, Mak B, Huynh K, **Kwan EM**, Fettke H, Tran B, Davis ID, Mahon KL, Stockler MR, Briscoe K, Marx GM, Du P, Yu J, Jia S, Joshua AM, Azad AA, Butler LM, Meikle PJ, Horvath LG. Association of ceramide metabolism with resistance to androgen receptor signalling inhibitors in metastatic prostate cancer, Poster Presentation, ESMO Congress 2021. Lugano, Switzerland.
47. Mak B, Lin HM, **Kwan EM**, Fettke H, Tran B, Davis ID, Mahon KL, Stockler MR, Briscoe K, Marx GM, Kohli M, Tan W, Huynh K, Du P, Yu J, Jia S, Joshua AM, Azad AA, Meikle PJ, Horvath LG. *Impact of combined lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer (mCRPC)*, Poster Presentation, ESMO Congress 2021. Lugano, Switzerland.
48. Pathmanandavel S, Crumbaker M, Yam AO, Rofe C, Ho B, Chan WL, Sharma S, Hickey AJ, Kongrak K, Ratnayake L, **Kwan EM**, Azad AA, Eu P, Nguyen A, Joshua AJ, Emmett L. Final results of a phase I/II prospective dose escalation trial evaluating safety and efficacy of combination ¹⁷⁷Lu-PSMA-617 and NOX66 in men with end-stage metastatic castration-resistant prostate cancer (LuPIN trial), Poster Presentation, ASCO GU, 2021. San Francisco, USA.
49. **Kwan EM**, Dai C, Fettke H, Hauser C, Bukczynska P, Ng N, Foroughi S, Graham LK, Mahon KL, Tan W, Wang A, Zhao Z, Zheng T, Zhou K, Yu J, Du P, Horvath LK, Jia S, Kohli M, Azad AA. *Plasma cell-free DNA*

profiling of PI3K/Akt pathway aberrations in two multi-institutional independent metastatic castration-resistant prostate cancer (mCRPC) cohorts, Poster Presentation, ASCO GU, 2021. San Francisco, USA.

50. Azad AA, Spain L, Anton A, Gan CL, Garrett L, Chang D, Bennett C, Kothari G, Shaw M, Parente P, Pezaro CJ, Tran B, Siva S, **Kwan EM**. ICEPAC: A phase II multicenter study of avelumab combined with stereotactic ablative body radiotherapy (SABR) in metastatic castration-resistant prostate cancer (mCRPC), Poster Presentation, ASCO GU, 2021. San Francisco, USA.
51. Fankhauser CD, Tran B , Ruiz-Morales JM , Gonzalez-Billalabeitia E , Patrikidou A , Amir E, Seidel C , Bokemeyer C, Hermanns T, Tryakin A, Rumyantsev A, Brito M, Flechon A, **Kwan EM**, Cheng T, Castellano D, Garcia Del Muro X, Hamid AA, Ottaviano M, Kitson R, Reid A , Heng DYC, Bedard PL, Sweeney CJ, Connors JM. *Venous thromboembolic events stratified by number of risk factors in patients with metastatic germ cell tumours undergoing first-line chemotherapy*, Oral Abstract Presentation, EAU Congress, 2020. Virtual.
52. **Kwan EM**, Fettke H, Bukczynska P, Ng N, Hauser C, Graham LK, Mahon K, Dai C, Xie F, Wang X, Zhao Z, Zhou K, Du P, Yu J, Jia S, Tan W, Horvath LG, Kohli M, Azad AA. *Plasma cell-free DNA (cfDNA) profiling of copy number variation (CNV) to identify poor prognostic biomarkers in metastatic castration-resistant prostate cancer (mCRPC)*, Poster Presentation, ASCO GU, 2020. San Francisco, USA.
53. Fankhauser CD, Tran B , Ruiz-Morales JM , Gonzalez-Billalabeitia E , Seidel C , Bokemeyer C, Hermanns T, Rumyantsev A, Brito M, Flechon A, **Kwan EM**, Castellano D, Garcia Del Muro X, Hamid AA, Ottaviano M, Reid A , Bedard PL, Sweeney CJ, Connors JM. *Benefit of prophylactic anticoagulation before and during first-line chemotherapy on patients with metastatic germ cell tumors*, Poster Presentation, ASCO GU, 2020. San Francisco, USA.
54. Schmidt A, Anton A, Shapiro J, Wong S, Azad AA, **Kwan EM**, Spain L, Muthusam A, Torres J, Parente P, Parnis F, Goh J, Joshua A, Pook D, Gibbs P, Tran B, Weickhardt A. *Treatment outcomes for metastatic castration-resistant prostate cancer patients following docetaxel for hormone-sensitive disease*, Poster Presentation, ASCO GU, 2020. San Francisco, USA.
55. Pereira-Salgado A, Tran B, **Kwan EM**, Angelyn A, Gibbs P, IJzerman MJ. *Real-world treatment sequencing of abiraterone and enzalutamide in metastatic castration-resistant prostate cancer – what are the health economic implications*, Poster Presentation, ISPOR Europe, 2019. Copenhagen, Denmark.
56. Chazan G, Anton A, Wong S, Shapiro J, Weickhardt A, Azad A, **Kwan EM**, Spain L, Muthusamy A, Torres J, Parente P, Parnis F, Goh J, Joshua A, Pook D, Gibbs P, Tran B. *Beyond cabazitaxel: late line treatments in metastatic castration resistant prostate cancer: a retrospective multicentre analysis*, **Oral Abstract Presentation**, COSA Annual Scientific Meeting, 2019. Adelaide, Australia.

57. Davies A, **Kwan EM**, Kourambas J, Redgrave N, Donnellan S, Appu S, Williams S, Coleman A, Foo M, Ramdave S, Azad AA. *⁶⁸Ga-prostate-specific membrane antigen (PSMA) PET/CT as a clinical decision-making tool in biochemically recurrent prostate cancer after definitive treatment: An Australian prospective study*, Poster Presentation, COSA Annual Scientific Meeting, 2019. Adelaide, Australia.
58. Davies A, **Kwan EM**, Briggs P, Segelov E. *Implementation of an immune-related adverse events education program for healthcare professionals at an Australian multicentre tertiary health service*, Poster Presentation, COSA Annual Scientific Meeting, 2019. Adelaide, Australia.
59. **Kwan EM**, Fettke H, Docanto M, To SQ, Bukczynska P, Mant A, Pook D, Ng N, Graham LK, Mangiola S, Segelov E, Mahon K, David ID, Parente P, Pezaro C, Todenofer T, Horvath LG, Azad AA. *Whole blood androgen receptor-based gene signature as a prognostic biomarker in metastatic castration-resistant prostate cancer*, Oral Abstract Presentation, ANZUP Annual Scientific Meeting, 2019. Brisbane, Australia. * Selected for “Best of the Best” session
60. Fettke H, **Kwan EM**, Yu J, Wang A, Montesinos C, Wong C, Gong X, Zheng T, Du P, Jia S, Mant A, Parente P, Pezaro C, Azad AA. *Prognostic and predictive utility of copy number variations in circulating tumour DNA from metastatic castrate-resistant prostate cancer patients*, Poster Presentation, ANZUP Annual Scientific Meeting, 2019. Brisbane, Australia.
61. Fettke H, **Kwan EM**, Mant A, Docanto M, Bukczynska P, Ng N, Parente P, Pezaro C, Azad AA. *Plasma cell-free DNA concentration and outcomes in metastatic castrate-resistant prostate cancer patients treated with androgen receptor pathway inhibitors*, Poster Presentation, ANZUP Annual Scientific Meeting, 2019. Brisbane, Australia.
62. Kelly R, Anton A, Wong S, Shapiro J, Weickhardt A, Azad AA, **Kwan EM**, Spain L, Muthusamy A, Torres J, Parente P, Parnis F, Goh J, Joshua A, Pook D, Gibbs P, Tran B. *Real-world use of first-generation anti-androgens: influence on patient outcome and subsequent therapies in metastatic castration-resistant prostate cancer*, Poster Presentation, ANZUP Annual Scientific Meeting, 2019. Brisbane, Australia.
63. Fettke H, **Kwan EM**, Yu J, Wang A, Montesinos C, Wong C, Gong X, Zheng T, Du P, Jia S, Mant A, Parente P, Pezaro C, Azad AA. *Prognostic and predictive utility of copy number variations (CNVs) in circulating tumor DNA (ctDNA) from metastatic castration-resistant prostate cancer (mCRPC) patients*, Poster Presentation, AACR, 2019. Georgia, USA
64. **Kwan EM**, To SQ, Fettke HC, Mant A, Docanto MM, Bukczynska P, Mant A, Pook D, Ng N, Graham LK, Segelov E, Mahon K, Davis ID, Parente P, Pezaro C, Horvath L, Azad AA. *Whole blood FOLH1 mRNA expression and treatment response in metastatic castration-resistant prostate cancer*, Poster Presentation, ASCO GU, 2019. San Francisco, USA.
65. **Kwan EM**, Semira M, Muttiah C, Beck S, Anton A, Tran B. *Changing treatment landscape in the initial management of metastatic castrate-resistant prostate cancer (mCRPC): an Australian multi-centre*

retrospective study, Oral Abstract Presentation, MOGA Annual Scientific Meeting, 2018. Adelaide, Australia.

66. Fettke HC, **Kwan EM**, Mant A, Docanto MM, Bukczynska P, To SQ, Waltham M, Ng N, Parente P, Pezaro C, Azad AA. *Plasma cell-free DNA concentration and outcomes in metastatic castrate-resistant prostate cancer patients treated with androgen receptor signalling inhibitors, Oral Abstract Presentation, ANZUP Annual Scientific Meeting, 2018. Sydney, Australia. * Selected for “Best of the Best” session*
67. **Kwan EM**, To SQ, Fettke HC, Mant A, Docanto MM, Martelotto L, Bukczynska P, Ng N, Graham LK, Parente P, Pezaro C, Mahon K, Horvath L, Todenofer T, Azad AA. *Whole blood AR-V7 and AR-V9 mRNA expression and treatment response in metastatic castrate-resistant prostate cancer, Poster Presentation, ASCO GU, 2018. San Francisco, USA. * Conquer Cancer Foundation Merit Award*
68. Lee CK, Scott CL, Lindeman GJ...**Kwan EM**, Boyle FM, Friedlander M. *Phase I study of olaparib, in combination with oral cyclophosphamide, in patients with metastatic triple negative breast cancer and recurrent high grade serous ovarian cancer, Poster Presentation, ASCO Annual Meeting, 2017. Chicago, USA*
69. Desai J, Markman B, Ananda S...**Kwan EM**, Waring PM, Tran B. *A phase I/II trial of combined BRAF and EGFR inhibition in patients with BRAF V600E mutated (BRAFm) metastatic colorectal cancer: The EViCT study, Poster Presentation, ASCO Annual Meeting, 2017. Chicago, USA*
70. **Kwan EM**, To SQ, Fettke HC, Mant A, Docanto MM, Martelotto L, Ng N, Graham LK, Parente P, Pezaro C, Mahon K, Horvath L, Todenofer T, Azad AA. *Detection of AR-V7 transcript in whole blood RNA of patients with metastatic castrate-resistant prostate cancer, Poster Presentation, ANZUP Annual Scientific Meeting, 2017. Melbourne, Australia. * Selected for “Best of the Best” session*
71. **Kwan E**, Lee B, Wong H, Nott L, Lee M, Wong R, Zimet A, Shapiro J, Burge M, Lipton L, Kosmider S, Gibbs P. *Use and impact of bevacizumab in patients undergoing liver resection in routine clinical practice, Poster Presentation, AGITG Annual Scientific Meeting, 2015. Melbourne, Australia. * Finalist for “First Forward” oral poster presentation session*
72. **Kwan E**, Phillips J, Hornung I, Greenberg S. *Review of an innovative health service approach, the Symptom Urgent Review Clinic (SURC), to improve efficiency and quality of care for breast cancer patients receiving adjuvant chemotherapy, Poster Presentation, Clinical Oncology Society of Australia Annual Scientific Meeting, 2015. Tasmania, Australia.*
73. Spain L, Dowling A, **Kwan E**, Pezaro C, Day D, Chia P, Tran B, Pook DW, Weickhardt A. *Pattern of presentation of brain metastases in metastatic renal cell cancer patients treated with targeted therapies: implications for screening practice, Poster Presentation, ESMO European Cancer Congress, 2015. Vienna, Austria.*

74. Day D, Kanjanapan Y, **Kwan E**, Yip D, Lawrentschuk N, Davis ID, Azad A, Rosenthal M, Arifeen S, Alam M, Gibbs P, Tran B. *Can neutrophil-to-lymphocyte ratio be used to identify patients with metastatic renal cell carcinoma who may gain greater benefit from cytoreductive nephrectomy?* Poster Presentation, ASCO GU, 2015. Florida, USA.
75. **Kwan E**, McLeod V, Pook DW. *Can supportive care screening predict testicular cancer surveillance compliance?* Poster Presentation, ANZUP Annual Scientific Meeting, 2014. Melbourne, Australia.
76. Kanjanapan Y, Day D, **Kwan E**, Lawrentschuk N, Andrews M, Davis ID, Azad A, Rosenthal M, Wong S, Arifeen S, Alam M, Gibbs P, Tran B, Yip D. *Sunitinib therapy for metastatic renal cell carcinoma (mRCC) in elderly patients (age 65 and older): a multi-institutional Australian experience,* Poster Presentation, ANZUP Annual Scientific Meeting, 2014. Melbourne, Australia.
77. Dai D, Kanjanapan Y, **Kwan E**, Yip D, Lawrentschuk N, Andrews M, Davis ID, Azad A, Rosenthal M, Wong S, Arifeen S, Alam M, Gibbs P, Tran B. *Patterns of care in Australian patients with metastatic renal cell carcinoma,* Poster Presentation, ANZUP Annual Scientific Meeting, 2014. Melbourne, Australia.